Zantac Litigation:
Key 2025–2026 Updates After Federal MDL Dismissal
Over 5,000 active cases in California’s JCCP No. 5150, with additional active dockets in Delaware and Illinois. State courts are allowing claims to proceed where the federal MDL was dismissed — bellwether trials expected in 2027. Our firm is accepting cases nationwide.
Federal vs. State Courts
Why State-Court Litigation Is Where the Action Is
The Zantac litigation has a unique procedural posture: the federal MDL was dismissed after the judge excluded plaintiffs’ general-causation experts, but state courts — applying different evidentiary standards — have ruled the opposite way, allowing expert testimony and keeping thousands of cases alive.
Federal MDL No. 2924 — S.D. Florida
Federal MDL: Dismissed
- Judge excluded plaintiffs’ general-causation experts under Daubert
- Without expert testimony, all claims were effectively dismissed
- Does not bind state courts operating under different evidentiary rules
JCCP No. 5150 — Alameda County, California
California: 5,000+ Cases Active
- Judge Evelio Grillo ruled plaintiffs’ experts may testify
- Over 5,000 active cases under coordinated proceedings
- Discovery ongoing; bellwether trials expected in 2027
Delaware Superior Court
Delaware: Claims Proceeding
- Court denied defendants’ motions to dismiss in 2025
- Bladder, stomach, liver, and esophageal cancer claims allowed to proceed
- Discovery orders compelling production of stability data and internal communications
Latest Developments · 2025–2026
What Is Happening in State-Court Zantac Litigation
- Discovery orders compelling key evidence — courts have ordered production of stability testing data, NDMA-formation analyses, and internal communications regarding the recall
- Delaware motions to dismiss denied (2025) — bladder, stomach, liver, and esophageal cancer claims are all proceeding in Delaware Superior Court
- California JCCP fully active — over 5,000 cases under coordinated proceedings before Judge Grillo in Alameda County, with bellwether selection underway
- Illinois state-court cases active — additional coordinated proceedings in Illinois courts expanding the overall docket
- Bellwether trials expected in 2027 — early state-court verdicts will establish case values and drive settlement negotiations across all active dockets
Eligibility
Are You a Victim? Who May Qualify?
You may qualify if you used Zantac (ranitidine) — whether prescription or over-the-counter — and were later diagnosed with a qualifying cancer. Both short-term and long-term users may be eligible depending on their diagnosis and exposure history.
Qualifying Cancer Diagnoses
- Bladder cancer
- Stomach cancer
- Liver cancer
- Pancreatic cancer
- Esophageal cancer
- Colorectal cancer
General Eligibility Factors
- Used Zantac (ranitidine) — prescription or OTC
- Developed a qualifying cancer diagnosis
- Diagnosis documented by a physician
- Able to identify approximate duration and frequency of use
Legal Theories & Damages
Liability & What You Can Recover
Liability Legal Theories
- Failure to warn
- Defective design
- Negligent misrepresentation
- Breach of implied warranty
- Negligent failure to recall
- Consumer protection statute violations
Damages What You Can Recover
- Medical expenses (past and future)
- Lost income and reduced earning capacity
- Pain and suffering
- Emotional distress
- Wrongful death damages
- Punitive damages for reckless conduct
Our Firm Is Now Accepting Zantac Cancer Cases
We represent individuals nationwide in active state-court Zantac litigation — tracking every development in California’s JCCP, Delaware Superior Court, and Illinois state courts to ensure our clients are positioned for the strongest possible recovery ahead of 2027 bellwether trials.
We handle these cases on a contingency fee basis — you pay nothing unless we win.